Forte Biosciences

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update. “Following a very extensive process by our Board, the management team and external advisors, Forte is excited to embark on a new path as we develop novel compounds for the treatment of autoimmune diseases, including potentially graft versus host disease (GvHD), alopecia areata

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

LOS ANGELES--(BUSINESS WIRE)---- $FBRX #FBRX--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or "the Company") (NASDAQ: FBRX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Forte announced after the market closed on September 2, 2021,...

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

The stock price of Forte Biosciences, Inc. (NASDAQ: FBRX) fell by 82.3% yesterday. This is why it happened.

FBRX Stock: 82.3% Decrease Explanation

Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.

Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate

Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. “We are appreciative of the clinical trial sites and the patients for participating in this trial and we are grateful to our investors for taking the risk to support the advancement of a new therapeutic modality for atopic dermatitis,” said Paul Wagner, CEO of Forte Biosciences.

Why Forte Biosciences Stock Is Down Over 80% Today

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX

The negative drug results led Chardan Capital Markets to slash its price target by 96% to $4 from $105.

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

The company announced dismal results from a phase 2 study of its only pipeline candidate.

Why Forte Biosciences Stock Is Imploding Today

Shares of Forte Biosciences Inc. FBRX, -4.45% plummeted 81.2% on heavy volume toward a record low in premarket trading Friday, after the biopharmaceutical company said it will no longer advance its lead product candidate FB-401, a treatment for atopic dermatitis. Trading volume spiked to 2.8 million shares ahead of the open, compared with the full-day average of about 754,000 shares.

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug FB-401 failed to meet a statistical significance, the company said.

Forte Biosciences Just Plummeted 80%: Here's Why

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI). Positive trends were observed in key secondary en

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis on September 7, 2021. Conference Call and Webcast Information Forte management will host a confere

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Investors need to pay close attention to for Forte Biosciences (FBRX) stock based on the movements in the options market lately.

Implied Volatility Surging for Forte Biosciences (FBRX) Stock Options

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces first quarter 2021 results and provides a general business update on May 10, 2021. “Forte has continued to make excellent progress in the fist quarter of 2021. As we have previously highlighted, our randomized clinical trial of FB-401 in atopic dermatitis patients 2 years of age and older, including adolescents and adults, completed enrollment. We

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general business update on May 10, 2021. Conference Call and Webcast Information Forte management will host a conference call and webcast on Monday, May 10th at 4.30 PM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International). The conference ID number

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Forte Biosciences is developing a first-in-class drug for eczema, which affects over 16M patients in the US.

Forte Biosciences: Microbiome Therapeutics For Skin Disease

The company's key product candidate is FB-401, a topical live biotherapeutic, with three therapeutic strains of commensal gram-negative bacteria Roseomonas mucosa. FB-401 is being developed in mild to moderate atopic dermatitis and has FDA Fast track designation based on Phase 1a/2 data.

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Amgen

American Express

Caterpillar

Alpha Architect International Quantitative Momentum ETF

JPMorgan Chase & Co

UnitedHealth Group

Vera Bradley

ViewRay

Walgreens

Two new breakout stocks for Week 13 of 2021 with better than 10% short-term upside potential. This past week one selection gained over 10% with KIRK +16.2% in the early part of the week before giving back all its gains and more.

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provides a general business update on March 24, 2021. “Forte made significant progress in the fourth quarter of 2020. In September, we initiated a randomized trial of FB-401 in atopic dermatitis patients, including adults and children 2 years of age and older. We are very pleased to announce that patien

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a general business update on March 24, 2021. Conference Call and Webcast Information Forte management will host a conference call and webcast on Wednesday, March 24th at 8:30 AM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International). The co

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Chardan Annual Microbiome Medicines Summit on March 8th, 2021. Webcast Information Forte management will host a webcast on Monday March 8th, 2021 at 1.00 PM Eastern Time. Participants may access the webcast through the following link: https://wsw.com/webcast/chard7/f

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Cowen Annual Health Care Conference on March 1, 2021. Webcast Information Forte management will host a webcast on Monday March 1st, 2021 at 4.00 PM Eastern Time. Participants may access the webcast through the following link: https://wsw.com/webcast/cowen81

Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st

FB-401 is a unique approach to atopic dermatitis containing three strains of bacteria that have shown the ability to induce tissue repair and reduce inflammation. FB-401 may present efficacy and safety advantages over commercial and clinical stage treatments.

News for Forte Biosciences Stock (FBRX)